Patent · US Active

Anti-CD19 antibodies with reduced immunogenicity

US8691952B2 · kind B2 · utility

8Cited by

56References

32Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Michael Super · Lexington, US
Jonathan Davis · Waltham, US
Pascal André Stein · Boston, US

Key dates

Filing date	Dec 29, 2006
Grant date	Apr 8, 2014
Priority date	—
Expiry date	Aug 28, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.